Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed Ord Shs (NQ: AFMD )

3.021 +0.401 (+15.31%)
Streaming Delayed Price Updated: 12:08 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Affimed Ord Shs

< Previous 1 2 3 4 5 6 7 Next >
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
From Affimed N.V.
Via GlobeNewswire
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
From Affimed N.V.
Via GlobeNewswire
Earnings Preview For Affimed
Via Benzinga
Analyst Ratings for Affimed
Via Benzinga
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
Affimed Reports 2022 Financial Results and Operational Progress
From Affimed N.V.
Via GlobeNewswire
4 Analysts Have This to Say About Affimed
Via Benzinga
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for
From Affimed N.V.
Via GlobeNewswire
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
From Affimed N.V.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 79 stocks hit new 52-week lows. 
Via Benzinga
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
From Affimed N.V.
Via GlobeNewswire
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
From Affimed N.V.
Via GlobeNewswire
Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
From Affimed N.V.
Via GlobeNewswire
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
From Affimed N.V.
Via GlobeNewswire
Dow Surges Over 250 Points; Weber Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 250 points on Monday 
Via Benzinga
Analyst Says Affimed's 'Innate Cell Engagers Like No Others,' Sees Mammoth Upside
H.C. Wainwright initiated coverage on Affimed NV (NASDAQ: AFMD), a clinical-stage biotechnology company focused on developing innate cell engagers (ICEs) for cancer treatment.  
Via Benzinga
Crude Oil Rises Sharply; Adicet Bio Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Monday 
Via Benzinga
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. 
Via Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH
From Affimed N.V.
Via GlobeNewswire
US Stocks Higher; Dow Rises Over 100 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Monday 
Via Benzinga
Citing Lack Of Durability, Affimed Scraps AFM13 Monotherapy Plans For NK Cell Combo
Via Benzinga
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
From Affimed N.V.
Via GlobeNewswire
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.